Eyenovia, Inc. EYEN announced the decision to terminate a phase III study evaluating its investigational drug-device product, ...

The analyst pointed out that while Eyenovia's pipeline and commercial products, including the newly launched clobetasol propionate ophthalmic solution 0.05%, hold value, the company's capital ...

Additional details will be shared after the evaluation is complete. The company currently has two FDA-approved products, Mydcombi and clobetasol propionate, which are indicated for in-office pupil ...

The unit was established following Pfizer’s acquisition of Hospira in 2015. Credit: Pfizer. Pfizer is currently assessing the potential divestiture of its hospital drugs unit, a division mainly ...

Pfizer is currently assessing the potential divestiture of its hospital drugs unit, a division mainly focused on antibiotics and sterile injectables used in hospitals and clinics, Reuters reported.

NEW YORK, Nov 12 (Reuters) - Pfizer (PFE.N), opens new tab is exploring the sale of its hospital drugs unit, as the drugmaker, which has been under pressure from activist investor Starboard Value ...

After a series of acquisitions and an activist investor’s accusation of overspending, Pfizer is exploring an opportunity to slim down by divesting its hospital drugs unit, Reuters reports ...

NEW YORK (Reuters) - Pfizer (PFE) is exploring the sale of its hospital drugs unit, as the drugmaker, which has been under pressure from activist investor Starboard Value, looks to divest non-core ...

Pfizer's stock underperforms the S&P 500, facing patent expirations and competition, yet offers a 6.3% forward dividend yield. Despite a positive Q3 earnings surprise, profitability remains weaker ...

Pfizer, a multinational pharmaceutical and biotechnology corporation, is now a $159 billion (by market cap) healthcare giant. With business and stock excess seemingly totally wrung out, and with ...

Pfizer plans to invest $1 billion in China in the next five years. Sun Pharma's JAK inhibitor Leqselvi was slapped with an injunction in a lawsuit with Incyte. And more. 1. UPDATED: AstraZeneca ...

Pfizer (NYSE: PFE) has announced plans to invest $1 billion in China by 2030, targeting accelerated innovation, diagnostics improvements, and support for the local biotechnology sector. The news ...